Holen Sie sich die Stockscreener-App
33.94
3.89%
1.27
Handel nachbörslich:
34.20
0.26
+0.77%
Schlusskurs vom Vortag:
$32.67
Offen:
$33.225
24-Stunden-Volumen:
2.78M
Relative Volume:
1.39
Marktkapitalisierung:
$5.80B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-354.30M
KGV:
-13.45
EPS:
-2.5234
Netto-Cashflow:
$-286.27M
1W Leistung:
+8.61%
1M Leistung:
-7.80%
6M Leistung:
-15.97%
1J Leistung:
+604.15%
1-Tages-Spanne:
$32.87
$34.19
1-Wochen-Bereich:
$31.48
$34.19
52-Wochen-Spanne:
$4.795
$43.73
Cogent Biosciences Inc Stock (COGT) Company Profile
Firmenname
Cogent Biosciences Inc
Sektor
Branche
Telefon
617-945-5576
Adresse
275 WYMAN STREET, WALTHAM
Compare COGT vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
COGT
Cogent Biosciences Inc
|
33.94 | 5.58B | 0 | -354.30M | -286.27M | -2.5234 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Cogent Biosciences Inc Stock (COGT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-16 | Fortgesetzt | Jefferies | Buy |
| 2025-11-10 | Hochstufung | Stifel | Hold → Buy |
| 2025-11-10 | Hochstufung | Wedbush | Neutral → Outperform |
| 2025-10-16 | Eingeleitet | Stifel | Hold |
| 2025-09-03 | Eingeleitet | Raymond James | Strong Buy |
| 2025-03-07 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-12-11 | Herabstufung | Needham | Buy → Hold |
| 2024-02-26 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2024-02-08 | Eingeleitet | Citigroup | Buy |
| 2023-12-11 | Herabstufung | Wedbush | Outperform → Neutral |
| 2023-12-08 | Eingeleitet | JP Morgan | Overweight |
| 2023-04-28 | Eingeleitet | Robert W. Baird | Outperform |
| 2023-03-27 | Fortgesetzt | H.C. Wainwright | Buy |
| 2022-12-14 | Eingeleitet | Needham | Buy |
| 2022-06-28 | Eingeleitet | Guggenheim | Buy |
| 2021-10-11 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-06-09 | Fortgesetzt | Jefferies | Buy |
| 2020-12-23 | Eingeleitet | Piper Sandler | Overweight |
| 2020-10-14 | Eingeleitet | Ladenburg Thalmann | Buy |
Alle ansehen
Cogent Biosciences Inc Aktie (COGT) Neueste Nachrichten
Assessing Cogent Biosciences (COGT) Valuation After A Strong Year And Recent Share Price Pullback - Yahoo Finance
Why is Cogent Biosciences stock up 4% today? By Investing.com - Investing.com Canada
Why is Cogent Biosciences stock up 4% today? - Investing.com
COGT Stock Chart | COGENT BIOSCIENCES INC (NASDAQ:COGT) - ChartMill
Cogent Biosciences (COGT) CEO Robbins gifts 320,000 shares in estate move - Stock Titan
COGT SEC FilingsCogent Biosciences Inc 10-K, 10-Q, 8-K Forms - Stock Titan
A Look At Cogent Biosciences (COGT) Valuation After New APEX And JAK2 Data Presentations Are Announced - Sahm
Could 2026 Mark A Transformational Year For Cogent Biosciences? - RTTNews
Cogent Biosciences (NASDAQ: COGT) group reports 9,043,903 shares - Stock Titan
Cogent Biosciences Announces Presentations of Pivotal APEX Trial Data and JAK2 V617F Program at EHA Congress 2026 - Moomoo
Cogent Biosciences Announces Multiple Presentations at the European Hematology Association (EHA) 2026 Congress - The Manila Times
TradingKey - TradingKey
Cogent Biosciences (COGT) Receives a Rating Update from a Top Analyst - The Globe and Mail
Pier Capital LLC Buys Shares of 46,260 Cogent Biosciences, Inc. $COGT - MarketBeat
Analysts Offer Insights on Healthcare Companies: Novo Nordisk (NVO), OnKure Therapeutics (OKUR) and Cogent Biosciences (COGT) - The Globe and Mail
Cogent Biosciences, Inc. $COGT Shares Purchased by Vanguard Group Inc. - MarketBeat
LifeSci Capital Maintains Cogent Biosciences(COGT.US) With Buy Rating, Maintains Target Price $55 - Moomoo
Piper Sandler Maintains Cogent Biosciences(COGT.US) With Buy Rating, Maintains Target Price $52 - Moomoo
Cogent Biosciences (COGT) Valuation After Wider Q1 Loss And Bezuclastinib Regulatory Progress - Yahoo Finance
A Quick Look at Today's Ratings for Cogent Biosciences(COGT.US), With a Forecast Between $45 to $55 - Moomoo
A Look At Cogent Biosciences (COGT) Valuation After First Quarter Earnings Loss And Strong One Year Share Price Run - Sahm
H.C. Wainwright raises Cogent stock price target to $55 on cash runway - Investing.com UK
Understanding the Setup: (COGT) and Scalable Risk - Stock Traders Daily
Cogent Biosciences Reports Recent Business Highlights and First Quarter 2026 Financial Results - Investing News Network
Cogent Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Cogent Biosciences (NASDAQ:COGT) Posts Quarterly Earnings Results, Hits Expectations - MarketBeat
Cogent Biosciences Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Bezuclastinib NDAs and cash into 2028 at Cogent Biosciences (NASDAQ: COGT) - Stock Titan
Cogent Biosciences 1Q 2026: Net loss $(97.4)M, EPS $(0.53) — 10-Q Summary - TradingView
Biotechnology company Cogent Biosciences, Inc.'s latest financial data shows that as of the end of the first quarter of 2026, the company held a total of $866.4 million in cash and cash equivalents. - Bitget
Cogent Biosciences (COGT) boosts cash to fund bezuclastinib NDAs and launch plans - Stock Titan
Cogent Biosciences Q1 net loss widens on higher expenses - TradingView
Cogent plans two bezuclastinib launches, says cash lasts into 2028 - Stock Titan
BRIEF-Cogent Biosciences Q1 Income From Operations USD -103.607 Million - TradingView
MSN Money - MSN
Pictet Asset Management Holding SA Boosts Holdings in Cogent Biosciences, Inc. $COGT - MarketBeat
Cogent Biosciences, Inc. (NASDAQ:COGT) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Cogent Biosciences Inc (NASDAQ:COGT) Shows Bullish Technical Breakout Setup with High Scores - ChartMill
Systemic Mastocytosis (SM) Treatment Market 2026-2035: - GlobeNewswire
Systemic Mastocytosis (SM) Treatment Market 2026-2035: Industry to More Than Double in Size, Led by Sanofi, AdvaCare Pharma, and Cogent Biosciences - Yahoo Finance
Teachers Retirement System of The State of Kentucky Invests $1.33 Million in Cogent Biosciences, Inc. $COGT - MarketBeat
Cogent Biosciences, Inc. (NASDAQ:COGT) Sees Large Drop in Short Interest - MarketBeat
Cogent Biosciences (COGT) Expected to Announce Quarterly Earnings on Tuesday - MarketBeat
Cogent Biosciences prices equity offering and 1.625% convertible senior notes - MSN
COGT Rise as FDA Accepts Bezuclastinib NDA in Non-Advanced SM - MSN
A Look At Cogent Biosciences (COGT) Valuation After New KRAS And ErbB2 Data At AACR 2026 - Sahm
The Technical Signals Behind (COGT) That Institutions Follow - Stock Traders Daily
[ARS] Cogent Biosciences, Inc. SEC Filing - Stock Titan
Finanzdaten der Cogent Biosciences Inc-Aktie (COGT)
Umsatz
Nettogewinn
Free Cashflow
ENV
Cogent Biosciences Inc-Aktie (COGT) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Fairmount Funds Management LLC | Director |
Mar 31 '26 |
Sale |
34.66 |
7,000,000 |
242,620,000 |
5,503,418 |
| Fairmount Funds Management LLC | Director |
Jan 22 '26 |
Sale |
36.40 |
3,500,000 |
127,400,000 |
5,503,418 |
0.98%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):